$14.82
1.69% today
Nasdaq, Feb 05, 04:17 pm CET
ISIN
US14070B1017
Symbol
CAPR
Sector
Industry

Capricor Therapeutics, Inc. Stock price

$15.07
+0.07 0.47% 1M
+11.30 299.73% 6M
+1.27 9.20% YTD
+11.17 286.41% 1Y
+10.83 255.42% 3Y
+13.58 911.41% 5Y
-39.93 72.60% 10Y
Nasdaq, Closing price Tue, Feb 04 2025
-0.11 0.72%
ISIN
US14070B1017
Symbol
CAPR
Sector
Industry

Key metrics

Market capitalization $685.23m
Enterprise Value $605.22m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 26.05
P/S ratio (TTM) P/S ratio 29.50
P/B ratio (TTM) P/B ratio 8.90
Revenue growth (TTM) Revenue growth 65.33%
Revenue (TTM) Revenue $23.23m
EBIT (operating result TTM) EBIT $-35.93m
Free Cash Flow (TTM) Free Cash Flow $-38.33m
Cash position $85.03m
EPS (TTM) EPS $-1.06
P/E forward negative
P/S forward 32.68
EV/Sales forward 28.86
Short interest 18.92%
Show more

Is Capricor Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

Capricor Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Capricor Therapeutics, Inc. forecast:

7x Buy
100%

Analyst Opinions

7 Analysts have issued a Capricor Therapeutics, Inc. forecast:

Buy
100%

Financial data from Capricor Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
23 23
65% 65%
100%
- Direct Costs 1.36 1.36
46% 46%
6%
22 22
67% 67%
94%
- Selling and Administrative Expenses 12 12
13% 13%
51%
- Research and Development Expense 45 45
37% 37%
192%
-35 -35
16% 16%
-149%
- Depreciation and Amortization 1.36 1.36
46% 46%
6%
EBIT (Operating Income) EBIT -36 -36
16% 16%
-155%
Net Profit -34 -34
17% 17%
-147%

In millions USD.

Don't miss a Thing! We will send you all news about Capricor Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Capricor Therapeutics, Inc. Stock News

Neutral
GlobeNewsWire
about one month ago
-If approved, deramiocel would be first approved therapy for Duchenne muscular dystrophy cardiomyopathy- -BLA submission triggers $10 million milestone payment to Capricor from Nippon Shinyaku- SAN DIEGO, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases...
Positive
Market Watch
about 2 months ago
Stem-cell research is on the cusp of a breakthrough that could come as soon as 2025, and two biotech companies with promising therapies stand to gain, according to a new report from Maxim Group on Thursday.
Positive
Seeking Alpha
2 months ago
Capricor Therapeutics is advancing deramiocel, an allogeneic cell therapy for DMD-related cardiomyopathy, with a rolling BLA submission and potential FDA approval by 2025. Deramiocel showed significant improvements in upper limb function and LVEF in Phase 2 trials, with ongoing open-label extension trials supporting long-term efficacy and safety. Despite promising prospects, Capricor's upside i...
More Capricor Therapeutics, Inc. News

Company Profile

Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of first-in-class biological therapies for the treatment of cardiac and other serious medical conditions. Its product candidate consists of CAP-1002, Cenderitide, Exosomes, CAP-1001, CU-NP and CSps. The company was founded in August 2005 and is headquartered in Beverly Hills, CA.

Head office United States
CEO Linda Marbán
Employees 102
Founded 1996
Website www.capricor.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today